Related references
Note: Only part of the references are listed.Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets
Teresa Reynolds Sousa et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2022)
Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study
Thomas Knuijver et al.
ADDICTION (2022)
Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research
David Bender et al.
PSYCHOPHARMACOLOGY (2022)
Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies
Lucas Silva Rodrigues et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2022)
Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history
Craig Pearson et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)
Substance-related exogenous psychosis: a postmodern syndrome
Giovanni Martinotti et al.
CNS SPECTRUMS (2021)
Death due to consumption of ibogaine: case report
Tijana Acimovic et al.
FORENSIC SCIENCE MEDICINE AND PATHOLOGY (2021)
A non-hallucinogenic psychedelic analogue with therapeutic potential
Lindsay P. Cameron et al.
NATURE (2021)
Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review
Bruno Romeo et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2021)
New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review
Fabrizio Schifano et al.
EXPERIMENTAL NEUROLOGY (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse
Matthias Luz et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2021)
Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature
Giovanni Martinotti et al.
BRAIN SCIENCES (2021)
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Emmanuelle A. D. Schindler et al.
NEUROTHERAPEUTICS (2021)
The Negative Affect of Protracted Opioid Abstinence: Progress and Perspectives From Rodent Models
Lola Welsch et al.
BIOLOGICAL PSYCHIATRY (2020)
Chronic pain and psychedelics: a review and proposed mechanism of action
Joel P. Castellanos et al.
REGIONAL ANESTHESIA AND PAIN MEDICINE (2020)
An analytical study of iboga alkaloids contained in Tabernanthe iboga-derived products offered by ibogaine treatment providers
Jose Carlos Bouso et al.
ARCHIVES OF CLINICAL PSYCHIATRY (2020)
Ibogaine therapy for addiction: Consumer views from online fora
Michaela Barber et al.
INTERNATIONAL JOURNAL OF DRUG POLICY (2020)
Novel treatment of opioid use disorder using ibogaine and iboga in two adults
Claire Wilson et al.
JOURNAL OF PSYCHEDELIC STUDIES (2020)
Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits
Soledad Marton et al.
FRONTIERS IN PHARMACOLOGY (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
IBOGAINE CONSUMPTION WITH SEIZURE-LIKE EPISODES, QTC-PROLONGATION, AND CAPTURED CARDIAC DYSRHYTHMIAS
James Grogan et al.
JOURNAL OF EMERGENCY MEDICINE (2019)
Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder
Thomas K. Brown et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2019)
Breaking the cycle of opioid use disorder with Ibogaine
Deborah C. Mash
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2018)
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study
Geoffrey E. Noller et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2018)
Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes
Thomas Kingsley Brown et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2018)
Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence
Thomas Knuijver et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2018)
Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives
Giovanni Martinotti et al.
BRAIN SCIENCES (2018)
Cardiac arrest after ibogaine intoxication
Christian Steinberg et al.
JOURNAL OF ARRHYTHMIA (2018)
Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine
Benjamin J. Malcolm et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2018)
Understanding the Healing Potential of Ibogaine through a Comparative and Interpretive Phenomenology of the Visionary Experience
James Rodger
ANTHROPOLOGY OF CONSCIOUSNESS (2018)
A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification
Alan K. Davis et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2018)
Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences
Annamarie Heink et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2017)
A CASE OF QT PROLONGATION AND TORSADES DE POINTES CAUSED BY IBOGAINE TOXICITY
Catherine Hildyard et al.
JOURNAL OF EMERGENCY MEDICINE (2016)
Ibogaine and addiction in the animal model, a systematic review and meta-analysis
M. Belgers et al.
TRANSLATIONAL PSYCHIATRY (2016)
Ibogaine-associated cardiac arrest and death: case report and review of the literature
Jessica A. Meisner et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2016)
Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients
Paul Glue et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2016)
Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report
Laurie Cloutier-Gill et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2016)
Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels
Charles W. O'Connell et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2015)
The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation
Xaver Koenig et al.
MOLECULES (2015)
Noribogaine is a G-protein biased κ-opioid receptor agonist
Emeline L. Maillet et al.
NEUROPHARMACOLOGY (2015)
Ascending-Dose Study of Noribogaine in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability
Paul Glue et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Mania Following Use of Ibogaine: A Case Series
Cole J. Marta et al.
AMERICAN JOURNAL ON ADDICTIONS (2015)
Treating drug dependence with the aid of ibogaine: A retrospective study
Eduardo Ekman Schenberg et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Mechanism of hERG Channel Block by the Psychoactive Indole Alkaloid Ibogaine
Patrick Thurner et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Using risk difference as opposed to odds-ratio in meta-analysis
Andrea Messori et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Fatal Case of a 27-Year-Old Male After Taking Iboga in Withdrawal Treatment: GC-MS/MS Determination of Ibogaine and Ibogamine in Iboga Roots and Postmortem Biological Material
Cedric Mazoyer et al.
JOURNAL OF FORENSIC SCIENCES (2013)
Effect of Iboga Alkaloids on μ-Opioid Receptor-Coupled G Protein Activation
Tamara Antonio et al.
PLOS ONE (2013)
Ibogaine related sudden death: A case report
Stavroula A. Papadodima et al.
JOURNAL OF FORENSIC AND LEGAL MEDICINE (2013)
Ibogaine-associated ventricular tachyarrhythmias
Ales Pleskovic et al.
CLINICAL TOXICOLOGY (2012)
Fatalities Temporally Associated with the Ingestion of Ibogaine
Kenneth R. Alper et al.
JOURNAL OF FORENSIC SCIENCES (2012)
Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders
Anita E. Autry et al.
PHARMACOLOGICAL REVIEWS (2012)
The anti-addictive drug ibogaine modulates voltage-gated ion channels and may trigger cardiac arrhythmias
Michael Kovar et al.
BMC Pharmacology & Toxicology (2011)
Ibogaine therapy in the treatment of opiate dependency
Peter Brackenridge
DRUGS AND ALCOHOL TODAY (2010)
The ibogaine medical subculture
Kenneth R. Alper et al.
JOURNAL OF ETHNOPHARMACOLOGY (2008)
Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter
Miriam T. Jacobs et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine
Dao-Yao He et al.
FASEB JOURNAL (2006)
Modulation of NMDA receptors in the cerebellum. 1. Properties of the NMDA receptor that modulate its function
M Llansola et al.
CEREBELLUM (2005)
Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption
DY He et al.
JOURNAL OF NEUROSCIENCE (2005)
Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration
SD Glick et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Choice of effect measure for epidemiological data
SD Walter
JOURNAL OF CLINICAL EPIDEMIOLOGY (2000)